Tag Archives: Back

Activist Starboard steps up revolt on Bristol-Celgene merger—and BMS strikes back

First came the news that activist investor Starboard Value had bought up shares of Bristol-Myers Squibb with the intention of scuttling its planned $ 74 billion buyout of Celgene. Then, last week, BMS’ largest institutional shareholder, Wellington Management, spoke out against the deal, prompting Starboard CEO Jeffrey Smith to dash off a letter to BMS… Read More »

Primatene Mist Coming Back; Some Docs Concerned

Jason Shandell, president, Amphastar Pharmaceuticals Inc., Rancho Cucamonga, CA. Sandy Walsh, spokeswoman, FDA. FDA: “CDER Conversation: Safely Using the Newly Available OTC Asthma Inhaler Primatene Mist.” James Li, MD, PhD, professor of medicine, Mayo Clinic, Rochester, MN; former president, American Academy of Allergy, Asthma & Immunology. Dacia Morris, spokeswoman, American Thoracic Society, New York City.… Read More »